Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry

Cytometry Part A

Volumn 83 A, Issue 4, 2013, Pages 403-408

  Saab, Lea ^a   Peluso, Jean ^a   Muller, Christian D ^a   Ubeaud Sequier, Genevieve ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Hepatic transporters; Idiosyncratic drug induced hepatotoxicity; MDR1; Microvolume cytometry; MRP2

Indexed keywords

ABCB1 PROTEIN, HUMAN; KETOLIDE; LIPOPOLYSACCHARIDE; MULTIDRUG RESISTANCE PROTEIN; NAPHTHYRIDINE DERIVATIVE; NEFAZODONE; NIMESULIDE; P GLYCOPROTEIN 2; P-GLYCOPROTEIN 2; QUINOLONE DERIVATIVE; SULFONAMIDE; TELITHROMYCIN; TRIAZOLE DERIVATIVE; TROVAFLOXACIN; TUMOR NECROSIS FACTOR ALPHA; XENOBIOTIC AGENT;

ARTICLE; CELL STRAIN HEPG2; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; LIVER; LIVER CELL; METABOLISM; METHODOLOGY; PATHOLOGY; TOXIC HEPATITIS; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; DRUG-INDUCED LIVER INJURY; FLOW CYTOMETRY; FLUOROQUINOLONES; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; INFLAMMATION; KETOLIDES; LIPOPOLYSACCHARIDES; LIVER; NAPHTHYRIDINES; P-GLYCOPROTEIN; P-GLYCOPROTEINS; SULFONAMIDES; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; XENOBIOTICS;

EID: 84875537173     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22263     Document Type: Article

References (14)

1. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16: 3041-3053.
2. Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010; 118: 7-18.
3. Deng X, Luyendyk JP, Ganey PE, Roth RA. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 2009; 61: 262-282.
4. Cosgrove BD, King BM, Hasan MA, Alexopoulos LG, Farazi PA, Hendriks BS, Griffith LG, Sorger PK, Tidor B, Xu JJ, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009; 237: 317-330.
5. Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, North C, Blomme EA, Roth RA. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2006; 316: 1080-1087.
6. Teng S, Piquette-Miller M. Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol Pharm 2008; 5: 67-76.
7. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004; 1: 27-42.
8. Yamaguchi S, Zhao YL, Nadai M, Yoshizumi H, Cen X, Torita S, Takagi K, Hasegawa T. Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother 2006; 50: 80-87.
9. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36: 205-216.
10. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Feng B, Kubik R, Hanson J, Urda E, et al. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 2006; 90: 451-459.
11. Fernandez C, Buyse M, German-Fattal M, Gimenez F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci 2004; 7: 359-371.
12. Fardel O, Le Vee M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metab Toxicol 2009; 5: 1469-1481.
13. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16: 5651-5661.
14. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006; 34: 1756-1763.